Want to see BIOA full AI Analyst Report?
BIOA Stock Chart & Stats
$18.49
-$0.31(-5.78%)
At close: 4:00 PM EST
$18.49
-$0.31(-5.78%)
Day’s Range― - ―
52-Week Range$4.07 - $24.00
Previous CloseN/A
Volume146.35K
Average Volume (3M)430.52K
Market Cap
$1.12B
Enterprise Value$514.87M
Total Cash (Recent Filing)$383.19M
Total Debt (Recent Filing)$4.03M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 12, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding44,452,736
10 Day Avg. Volume481,106
30 Day Avg. Volume430,516
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)1.75
Price to Sales (P/S)52.85
P/FCF Ratio-5.77
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue49.91
Enterprise Value/Gross Profit50.22
Enterprise Value/Ebitda-5.77
Forecast
1Y Price Target
$37.25Price Target Upside101.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.56
Revenue Forecast (FY)$53.91M
Bulls Say, Bears Say
Bulls Say
High Gross Margin And Revenue GrowthSustained ~72% gross margin with ~14.7% revenue growth indicates the business model has pricing power and early commercial traction. These characteristics support scalable profitability as revenues grow, making margin expansion a durable path toward improved operating results over months.
Conservative Leverage And Asset CushionVery low debt relative to a sizable equity and asset base provides financial flexibility and reduces short-term solvency risk. This conservative capital structure gives management runway to fund R&D or pursue partnerships without immediate liquidity stress, a durable buffer over several quarters.
Governance Continuity And Audit OversightReelection of directors and retention of a Big Four auditor strengthen governance continuity and financial oversight. Robust board and reputable audit processes reduce execution and reporting risk, supporting steady long-term program execution and investor confidence across reporting cycles.
Bears Say
Large Cash BurnRun-rate cash outflows near ~$88M annually create a structural financing need absent rapid revenue scaling or cost reductions. Persistent negative cash flow increases dilution risk from capital raises and constrains strategic optionality until the company materially reduces burn or secures stable funding.
Significant Operating And Net LossesLarge recurring operating and net losses show the company remains pre-profit despite revenue growth. This negative profitability impairs return metrics and means the business must rely on external capital or partnerships for continued R&D and commercialization, limiting self-funded growth.
Ongoing Financing DependenceEven with low leverage and strong asset cushions, the magnitude of losses and cash burn creates sustained dependence on external financing. That reliance is a structural constraint affecting strategic choices, potential dilution, and vulnerability to capital market conditions over the medium term.
BioAge Labs, Inc. News
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $4.07 and its highest was $24.00 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $1.12B.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 39 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on May 08, 2026. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.64 by $0.12.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.61.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 44,452,736 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.64. Following the earnings report the stock price went up 0.954%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioAge Labs, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.25 (101.46% Upside)
$37.25 (101.46% Upside)
Blogger Sentiment
Bearish
BIOA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 28.2%
Last 30 Days ▲ 28.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
491.98%
12-Months-Change
Fundamentals
Return on Equity
-29.40%
Trailing 12-Months
Asset Growth
15.65%
Trailing 12-Months
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
BIOA Stock 12 Month Forecast
Average Price Target
$37.25
▲(101.46% Upside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
9.55% Insiders
6.42% Mutual Funds
44.02% Other Institutional Investors
29.57% Public Companies and
Individual Investors